eGlint

About eGlint

eGlint has developed the ProteoNex™ technology, a miniature biosensing device that quantifies multiple biomarkers from a small blood sample in under five minutes without the need for sample purification. This technology addresses the urgent need for rapid and cost-effective diagnostics, particularly in critical conditions like sepsis, where timely intervention can significantly reduce mortality rates.

```xml <problem> Current diagnostic methods for conditions like sepsis often require lengthy sample purification processes and can be slow, hindering timely intervention and potentially increasing mortality rates. Rapid and cost-effective diagnostic tools are needed, especially in critical care settings where immediate results can significantly improve patient outcomes. </problem> <solution> eGlint has developed ProteoNex™, a technology that enables real-time biomarker testing directly from a small blood sample, eliminating the need for sample purification and delivering results in under five minutes. The ProteoNex™ technology is versatile, allowing it to measure combinations of virtually any biomarkers. This rapid, highly multiplexed, and quantitative approach provides clinicians with actionable insights for faster and more informed decision-making in critical conditions like sepsis. The affordable and scalable nature of the technology lowers the cost per sample and dramatically reduces the cost per biomarker, making it accessible for widespread use. </solution> <features> - ProteoNex™ technology quantifies virtually any biomarker from a drop of blood. - Performs hundreds of assays simultaneously. - Delivers results within minutes without sample purification. - Lowers cost per sample and dramatically reduces cost per biomarker. </features> <target_audience> The primary target audience includes healthcare providers and diagnostic laboratories seeking rapid, cost-effective, and highly multiplexed biomarker testing solutions for critical conditions like sepsis. </target_audience> ```

What does eGlint do?

eGlint has developed the ProteoNex™ technology, a miniature biosensing device that quantifies multiple biomarkers from a small blood sample in under five minutes without the need for sample purification. This technology addresses the urgent need for rapid and cost-effective diagnostics, particularly in critical conditions like sepsis, where timely intervention can significantly reduce mortality rates.

Where is eGlint located?

eGlint is based in San Diego, United States.

When was eGlint founded?

eGlint was founded in 2021.

How much funding has eGlint raised?

eGlint has raised $2.4M.

Location
San Diego, United States
Founded
2021
Funding
$2.4M
Employees
6 employees
Investors
Gloucesterventures

eGlint

4
Relative Traction Score based on online presence metrics compared to companies in the same age group.

Executive Summary

eGlint has developed the ProteoNex™ technology, a miniature biosensing device that quantifies multiple biomarkers from a small blood sample in under five minutes without the need for sample purification. This technology addresses the urgent need for rapid and cost-effective diagnostics, particularly in critical conditions like sepsis, where timely intervention can significantly reduce mortality rates.

eglint.com200+
Founded 2021 – San Diego, United States

Funding

No specific funding rounds found.

Total Funding

$2.4M

Backed by

Gloucesterventures

Team (5+)

No team information available.

Company Description

Problem

Current diagnostic methods for conditions like sepsis often require lengthy sample purification processes and can be slow, hindering timely intervention and potentially increasing mortality rates. Rapid and cost-effective diagnostic tools are needed, especially in critical care settings where immediate results can significantly improve patient outcomes.

Solution

eGlint has developed ProteoNex™, a technology that enables real-time biomarker testing directly from a small blood sample, eliminating the need for sample purification and delivering results in under five minutes. The ProteoNex™ technology is versatile, allowing it to measure combinations of virtually any biomarkers. This rapid, highly multiplexed, and quantitative approach provides clinicians with actionable insights for faster and more informed decision-making in critical conditions like sepsis. The affordable and scalable nature of the technology lowers the cost per sample and dramatically reduces the cost per biomarker, making it accessible for widespread use.

Features

ProteoNex™ technology quantifies virtually any biomarker from a drop of blood.

Performs hundreds of assays simultaneously.

Delivers results within minutes without sample purification.

Lowers cost per sample and dramatically reduces cost per biomarker.

Target Audience

The primary target audience includes healthcare providers and diagnostic laboratories seeking rapid, cost-effective, and highly multiplexed biomarker testing solutions for critical conditions like sepsis.

Sources:

1
This profile is AI-generated from web data and may contain inaccuracies. Want to correct or remove an entry? Owners can claim edits via their company email domain, and signed-in users can submit sourced suggestions.